Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as first-line treatment for gastric cancer with peritoneal metastasis: a single-arm phase 2 trial (DRAGON-09).

EClinicalMedicine · 2026 · PMC12803849 · PMID 41542221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

An exploratory analysis of PFS and OS stratified by PD-L1 CPS score showed a trend of PFS benefit in CPS ≥1, ≥5 population ( Supplementary Figure S3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.